Organelle-Targeted Nanotherapeutics for Parkinson’s Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s607870 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von MaoYu Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Parkinson Disease, Organelles, Nanoparticle Drug Delivery System, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons and the aggregation of αSynuclein (αSyn). Organelle dysfunction is recognized as a central driver of pathological feature. Current treatments primarily alleviate symptoms but fail to halt disease progression, largely due to the inability to target the underlying subcellular pathology. This narrative review examines the emerging potential of organelle-targeted nanotherapeutics as a precision medicine strategy for PD treatment. We discuss how engineered nanoparticles can be designed to deliver therapeutics specifically to dysfunctional mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus, and nuclei. These approaches aim to interfere with key pathological mechanisms ameliorating oxidative stress, mitigating protein misfolding, restoring protein homeostasis, and modulating gene expression. We provide a comprehensive overview of recent preclinical advances in nanoparticles design, targeting mechanisms, and therapeutic efficacy. Furthermore, we critically evaluate the current challenges, including delivery efficiency, safety, reproducibility, storage, and large-scale translation before clinical application This review aims to provide a potential route toward disease-modifying nanotherapeutics for PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
ORCID-Profile: Heng Zhai, ZhiCheng Tang, Haoxuan Ouyang
Zitieren
APA
Liu, M., Peng, Q., Zhai, H., Wu, Y., Ma, Z., Tang, Z., Ouyang, H., Chang, A., Cao, X., Xu, Y., & Xia, Y. (2026). Organelle-Targeted Nanotherapeutics for Parkinson’s Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s607870
Vancouver
Liu M, Peng Q, Zhai H, Wu Y, Ma Z, Tang Z, et al. Organelle-Targeted Nanotherapeutics for Parkinson’s Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s607870
BibTeX
@article{Liu2026,
author = {Liu, MaoYu and Peng, QiWei and Zhai, Heng and Wu, Yi and Ma, ZhuoRan and Tang, ZhiCheng and Ouyang, Haoxuan and Chang, An and Cao, XueBing and Xu, Yan and Xia, Yun},
title = {Organelle-Targeted Nanotherapeutics for Parkinson’s Disease: From Pathogenesis to Preclinical Strategies and Translational Challenges},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s607870}
}
EUVIMED